HomeQuestion

How you choose between letrozole or exemestane when patients have AIMSS with anastrozole in adjuvant breast cancer therapy?

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

Would you consider adding adjuvant ribociclib for a patient who has already received 2 years of endocrine therapy and is eligible for ribociclib according to the NATALEE trial?

What adjuvant therapy would you recommend for a woman in her 90s with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?

How would you treat a patient with bilateral breast cancer, HER2 positive on one side and HER2 negative on the contralateral side, specifically in regards to adjuvant CDK4/6i vs neratinib?

Would you offer adjuvant ribociclib to a postmenopausal female with ER+ luminal A, node+ breast cancer pT1cN1a grade 2 that didn't require chemotherapy per Oncotype, but met NATALEE inclusion criteria?

What are your top takeaways in Medical Oncology from SABCS 2025?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.